SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : momo-T/FIF -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (11636)8/9/2018 2:43:53 PM
From: scaram(o)uche  Read Replies (1) | Respond to of 12215
 
>> I do see a report of of one patient who had 17 doses of PRS-050 developing ADAs <<

Believe that patient was one of the 24 who did NOT show an antibody response, and that they were only singling that individual out for having been exposed repeatedly.

Biweekly dosing, bled for antibody testing four weeks after last dose. Direct ELISA. Not bad, but not exhaustive. Direct ELISAs can selectively hide epitopes.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News